Recent Advancements in Drug Delivery Across the Blood–Brain Barrier in Amyotrophic Lateral Sclerosis ( ALS )
CNS Neuroscience & Therapeutics · 2026-09 · 32 (9)
DOI: 10.1002/cns.71078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 11.09.2026. Verfasst von Nitesh Sanghai und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Blood-Brain Barrier, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant, CIHR, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Background
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal motor neurodegenerative disease with limited therapeutic options. The blood–brain barrier (BBB) and blood‐spinal cord barrier (BSCB) present major obstacles to central nervous system (CNS) drug delivery, restricting the effectiveness of many potential therapies. Increasing evidence suggests that BBB and BSCB dysfunction are not only barriers to treatment but also important contributors to ALS pathophysiology.
Objective
To examine current evidence regarding BBB and BSCB dysfunction in ALS and evaluate the implications of stage‐dependent barrier alterations for CNS drug delivery and therapeutic outcomes.
Methods
Recent mechanistic, pathological, preclinical, and clinical studies examining BBB and BSCB alterations in ALS were reviewed. Evidence on tight junction disorganization, endothelial dysfunction, vascular leakage, altered transporter activity, and emerging therapeutic and drug delivery strategies was analyzed.
Results
Converging evidence indicates that BBB and BSCB dysfunction are intrinsic and progressive features of ALS pathophysiology rather than passive consequences of neurodegeneration. Barrier impairment emerges early in the disease course and evolves across clinical stages. Disruption of barrier integrity may increase motor neuron vulnerability while modulating CNS drug exposure. Emerging strategies that bypass, exploit, or restore barrier function hold promise for enhancing CNS bioavailability and improving therapeutic outcomes.
Conclusions
Improved understanding of barrier alterations may facilitate development of more effective CNS‐targeted therapies and improve therapeutic outcomes in ALS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
- Cellular and Molecular Medicine Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Neurobiology, University of Chicago, Chicago, Illinois, USA.
- Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri, USA.
- Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- Institute of Neuroscience, UCLouvain, Brussels, Belgium.
ORCID-Profile: Nitesh Sanghai, Kaitlyn Pierce, Nidhi Sharma, Sasha Leggett, Pegah Masrori, Devi Atukorallaya, Senthilnathan Palaniyandi, Paul C Marcogliese, Geoffrey K Tranmer
Förderung
- Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant
- CIHR
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
Zitieren
APA
Sanghai, N., Pierce, K., Sharma, N., Leggett, S., Yadav, T. C., Masrori, P., Atukorallaya, D., Palaniyandi, S., Marcogliese, P. C., & Tranmer, G. K. (2026). Recent Advancements in Drug Delivery Across the Blood–Brain Barrier in Amyotrophic Lateral Sclerosis ( ALS ). CNS Neuroscience & Therapeutics, 32(9). https://doi.org/10.1002/cns.71078
Vancouver
Sanghai N, Pierce K, Sharma N, Leggett S, Yadav TC, Masrori P, et al. Recent Advancements in Drug Delivery Across the Blood–Brain Barrier in Amyotrophic Lateral Sclerosis ( ALS ). CNS Neuroscience & Therapeutics. 2026;32(9). doi:10.1002/cns.71078
BibTeX
@article{Sanghai2026,
author = {Sanghai, Nitesh and Pierce, Kaitlyn and Sharma, Nidhi and Leggett, Sasha and Yadav, Tara Chand and Masrori, Pegah and Atukorallaya, Devi and Palaniyandi, Senthilnathan and Marcogliese, Paul C and Tranmer, Geoffrey K},
title = {Recent Advancements in Drug Delivery Across the Blood–Brain Barrier in Amyotrophic Lateral Sclerosis ( ALS )},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {9},
doi = {10.1002/cns.71078}
}
EUVIMED